The most effective way to treat rheumatoid arthritis is to prevent it.
We developed a test that accurately identifies patients that will develop rheumatoid arthritis within 3 years. Our mission is to substantially reduce the high burden of this disease by helping rheumatologists worldwide identify these high-risk patients in order to start preventive therapy.
Preventing Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects 1% of the population worldwide. RA causes irreversible damage to joints. Although a treatment does exists, patients are rarely treated in time. The societal costs for RA in the USA alone is 39 billion dollar per year. Current diagnostic tests are not sensitive enough to predict disease onset, showing as much as 72% false positives. Therefore, patients need to wait until the disease fully develops before getting any treatment. At this point, some of the damage done by the disease is already irreversible. This results in increased societal and medical costs. For this reason, early prediction is key to prevention of RA.
Patented test as a service
Precision ImmunOmics has developed a test that allows 91% prediction of developing RA. The patented test has already been validated on 300 individuals followed up to 8 years and uses a proprietary highthroughput next generation sequencing technology. We aim to make this test a standard diagnostic test for the prevention of RA. Precision Immunomics will offer this test as a service to rheumatologists. Analysis will be done in our facilities that are already up and running. In the next years we plan to get CE and IVD certifications for the European and US markets.
The team consists of Marieke BackerA, MBA, Prof Antoine van KampenB, Sabrina PollastroA, PhD student, and Dr. Niek de VriesA, Consultant Rheumatology, AMC Principle Investigator & Location head. ADepartment of Clinical Immunology & Rheumatology, AMC, Amsterdam BDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, AMC, Amsterdam
- Venture Challenge Spring 2018
- Niek de Vries | email@example.com